8-K: Propanc Biopharma Secures $50,000 Convertible Note to Bolster Working Capital

Propanc Biopharma, Inc. has entered into a securities purchase agreement for a $50,000 convertible promissory note to enhance its working capital.

Summary

• Propanc Biopharma, Inc. has secured a $50,000 convertible promissory note from 104 LLC.
• The actual purchase price of the note was $46,875, with an original issue discount of $3,125.
• The note carries an 8% annual interest rate, with the first twelve months of interest ($4,000) guaranteed.
• The maturity date is twelve months from the issue date, March 1, 2024.
• The note can be converted into common stock at 65% of the lowest daily closing trade price in the previous ten trading days, representing a 35% discount.
• The conversion is subject to a 4.99% beneficial ownership limitation.
• The company is required to reserve a minimum of 134,000,000 shares of common stock or five times the number of shares issuable upon full conversion of the note.
• The company has the option to prepay the note within the first six months with a premium ranging from 110% to 125% depending on the timing.
• The note has priority over all unsecured indebtedness of the company.
• The company is restricted from incurring additional senior or pari passu unsecured debt, paying dividends, repurchasing stock, or selling significant assets without the holder's consent.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While the company is raising capital, the terms of the note are fairly standard and include some restrictions. The company's ability to repay the note and avoid dilution will depend on its future performance.

Positives

• The convertible note provides immediate capital for working capital purposes.
• The conversion feature offers potential upside for the note holder.
• The prepayment option provides flexibility for the company.
• The note's priority over unsecured debt offers some security to the investor.

Negatives

• The note includes a significant original issue discount of $3,125.
• The conversion price is subject to market fluctuations, which could dilute existing shareholders.
• The company is subject to various restrictions on its financial activities.
• Failure to meet obligations under the note can trigger an event of default.

Risks

• The company's ability to repay the note depends on its financial performance.
• The conversion of the note could significantly dilute existing shareholders.
• The company is subject to various financial restrictions that could limit its flexibility.
• The company's failure to maintain its listing on a principal market could trigger an event of default.
• The company's failure to comply with SEC reporting requirements could trigger an event of default.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes. The note's conversion feature and prepayment options provide flexibility for both the company and the investor.

Management Comments

• The company intends to use the net proceeds therefrom for general working capital purposes.

Industry Context

This type of financing is common for small and micro-cap companies seeking to raise capital. The convertible note structure allows investors to participate in potential upside while providing the company with immediate funding.

Comparison to Industry Standards

• The 35% discount on the conversion price is relatively standard for this type of financing.
• The 8% interest rate is within the typical range for convertible notes issued by small-cap companies.
• The prepayment premium structure is also common, incentivizing early repayment while providing a return to the investor.
• The 4.99% beneficial ownership limitation is a common clause to prevent hostile takeovers or undue influence by a single investor.
• The requirement to reserve a large number of shares for potential conversion is also standard practice to ensure sufficient shares are available.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may benefit from the increased working capital.
• Creditors may be impacted by the note's priority over unsecured debt.
• Customers and suppliers may not be directly impacted by this transaction.

Next Steps

• The company will use the proceeds for working capital.
• The company will need to manage its financial obligations under the note.
• The company will need to monitor its stock price to manage potential dilution from conversion.
• The company will need to comply with all covenants and reporting requirements.

Key Dates

Keywords

convertible note, promissory note, working capital, securities purchase agreement, common stock, conversion price, beneficial ownership, prepayment, default, dilution